Who Owns Schrödinger Company?

Schrödinger Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Schrödinger?

Understanding a company's ownership is key to grasping its strategy and priorities. Schrödinger, a scientific software and biotech firm, saw its ownership evolve significantly after its February 2020 IPO.

Schrödinger, established in 1990, pioneered physics-based computational platforms for drug discovery and materials science. Their technology aims to speed up R&D by accurately predicting molecular and material properties.

Who owns Schrödinger Company?

Schrödinger, Inc. was founded in 1990 by Richard A. Friesner and W. Clark Still. Dr. Friesner continues to be involved as a board member and Scientific Advisory Chairman. Another account also names William A. Goddard III as a co-founder alongside Dr. Friesner.

Founding Year

The company was established in 1990, marking the beginning of its journey in computational chemistry.

Key Founders

Richard A. Friesner and W. Clark Still are recognized as the primary founders. William A. Goddard III is also cited as a co-founder.

Initial Focus

The company's initial business model centered on developing and licensing advanced molecular simulation software.

Founders' Vision

The founding team aimed to provide sophisticated computational tools to address the need for accurate molecular interaction modeling in scientific research.

Early Funding Landscape

For deep-tech ventures at the time, early funding typically originated from academic grants and angel investments.

Current Founder Involvement

Dr. Richard Friesner remains actively involved with the company as a board member and Scientific Advisory Chairman.

While specific details regarding the initial equity distribution or the exact amount of capital raised at the company's inception are not publicly detailed, the founders' vision was to create powerful computational tools essential for drug discovery and materials science. This focus on accurate molecular modeling addressed a significant gap in the scientific community. The early stages of such deep-tech ventures often relied on a combination of academic grants and investments from angel investors to fuel development. Information regarding early backers, specific angel investors, friends and family stakes, founder exits, or initial ownership disputes was not found in the available data.

Schrödinger's Foundational Years

Schrödinger was established in 1990 with a clear objective to advance molecular simulation software. The company's early strategy focused on licensing these sophisticated tools to researchers.

• Founding Year: 1990
• Primary Founders: Richard A. Friesner, W. Clark Still
• Co-Founder Mentioned: William A. Goddard III
• Core Business: Molecular simulation software development and licensing
• Key Application Areas: Drug discovery, materials science
• Founders' Vision: Accurate molecular interaction modeling

Schrödinger SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Schrödinger, Inc.'s ownership structure was significantly reshaped by its Initial Public Offering (IPO) on Nasdaq on February 6, 2020. This public debut provided substantial capital, altering the landscape of who owns Schrödinger company and its future direction.

The transition to a publicly traded entity marked a pivotal moment for Schrödinger, influencing its growth trajectory and strategic partnerships. The company's financial health, as indicated by its revenue and cash reserves, supports its ongoing research and development efforts. The Schrödinger company ownership structure, with a strong institutional presence, suggests a focus on long-term value creation.

Schrödinger's Ownership Dynamics

Schrödinger's ownership is heavily dominated by institutional investors, reflecting confidence in its business model and future prospects. This concentration of ownership can impact strategic decisions and governance.

• The IPO on February 6, 2020, was a key event in Schrödinger company ownership structure explained.
• Institutional investors held 93.25% of shares as of May 2025.
• Major institutional shareholders include BlackRock, Inc. and the Bill & Melinda Gates Foundation Trust.
• The Bill & Melinda Gates Foundation Trust, along with other D. E. Shaw entities, collectively held over 40% of stock as of July 31, 2024.
• Understanding who owns Schrödinger is crucial for assessing its market position and Competitors Landscape of Schrödinger.

Schrödinger PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Schrödinger's board of directors comprises a blend of its founders, representatives from significant investors, and independent experts. As of July 2025, the board includes Michael Lynton as Chairman, Ramy Farid as President & CEO, and Richard A. Friesner as Co-founder and Scientific Advisory Chairman, alongside other notable members. Bridget van Kralingen joined the board in March 2025, contributing her extensive experience in scaling global software businesses.

Schrödinger's voting power is structured through two classes of common stock: voting common stock and limited common stock. As of April 21, 2025, the company had 64,209,652 shares of common stock and 9,164,193 shares of limited common stock outstanding. Each share of common stock carries one vote, while limited common stock holders cannot vote on director elections or removals. However, limited common stock can be converted into common stock at any time. Significant influence over the company's direction is held by entities such as the Bill & Melinda Gates Foundation Trust, Schrödinger Equity Holdings, LLC, and various D. E. Shaw entities, which collectively owned over 40% of the total outstanding shares as of July 31, 2024. This substantial ownership stake means these entities have considerable sway in corporate decisions. Directors can only be removed for cause, requiring at least a majority vote of the common stock holders, but this is contingent on a 'Trigger Date' when the aforementioned major shareholders no longer collectively own more than 40% of the outstanding shares. There have been no reported proxy battles or activist investor campaigns concerning the company's governance.

Understanding Schrödinger's Ownership and Board Dynamics

Schrödinger's ownership structure is characterized by a dual-class stock system and significant influence from key institutional investors. The board composition reflects a balance between internal expertise and external strategic oversight.

• Schrödinger has both voting and limited common stock.
• Major shareholders collectively hold over 40% of outstanding shares as of July 31, 2024.
• Director removal requires a majority vote of common stock holders after a specific trigger event.
• Bridget van Kralingen's addition in March 2025 highlights a focus on global software business growth.
• For a deeper dive into the company's history, see the Brief History of Schrödinger.

Schrödinger Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the last few years, the ownership of Schrödinger has remained predominantly with institutional investors. As of May 2025, these large entities controlled a significant majority of the company's shares, indicating a stable, long-term investment focus.

Schrödinger has actively pursued strategic collaborations, reinforcing its business model and research capabilities. These partnerships are crucial for advancing its drug discovery programs and expanding its reach within the pharmaceutical industry. The company's progress in its proprietary programs also signals continued growth and innovation.

Strategic Collaborations Drive Growth

In January 2025, a significant $150 million upfront payment was received from Novartis for a new drug discovery collaboration. This highlights the value placed on Schrödinger's platform by major pharmaceutical players.

Expanded Research Efforts

Further strengthening its industry ties, Schrödinger expanded its research collaboration with Otsuka Pharmaceutical Co., Ltd. in January 2025 to encompass an additional, undisclosed target.

Insider Holdings and Compensation

Insider holdings saw a minor increase to 2.05% by May 2025. While insiders acquired more shares than they sold over the past year, most acquisitions were stock grants as compensation, rather than direct market purchases.

Proprietary Program Advancements

The company is on track to report initial Phase 1 data from its three proprietary programs during 2025. This progress is a key indicator of the company's internal research and development success.

Schrödinger Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔